- Home
- ATYR vs NKSH Comparison
ATYR vs NKSH Comparison
Compare ATYR & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- NKSH
- Stock Information
- Founded
- ATYR 2005
- NKSH 1891
- Country
- ATYR United States
- NKSH United States
- Employees
- ATYR N/A
- NKSH N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- NKSH Major Banks
- Sector
- ATYR Health Care
- NKSH Finance
- Exchange
- ATYR Nasdaq
- NKSH Nasdaq
- Market Cap
- ATYR 228.1M
- NKSH 182.9M
- IPO Year
- ATYR 2015
- NKSH N/A
- Fundamental
- Price
- ATYR $3.30
- NKSH $29.25
- Analyst Decision
- ATYR Strong Buy
- NKSH Strong Buy
- Analyst Count
- ATYR 4
- NKSH 1
- Target Price
- ATYR $19.25
- NKSH $38.00
- AVG Volume (30 Days)
- ATYR 832.1K
- NKSH 15.9K
- Earning Date
- ATYR 11-07-2024
- NKSH 10-24-2024
- Dividend Yield
- ATYR N/A
- NKSH 5.02%
- EPS Growth
- ATYR N/A
- NKSH N/A
- EPS
- ATYR N/A
- NKSH 1.44
- Revenue
- ATYR $235,000.00
- NKSH $43,450,000.00
- Revenue This Year
- ATYR N/A
- NKSH N/A
- Revenue Next Year
- ATYR $1,200.54
- NKSH $14.93
- P/E Ratio
- ATYR N/A
- NKSH $20.81
- Revenue Growth
- ATYR N/A
- NKSH N/A
- 52 Week Low
- ATYR $1.34
- NKSH $26.50
- 52 Week High
- ATYR $3.80
- NKSH $35.00
- Technical
- Relative Strength Index (RSI)
- ATYR 52.43
- NKSH 34.12
- Support Level
- ATYR $3.05
- NKSH $30.80
- Resistance Level
- ATYR $3.26
- NKSH $31.00
- Average True Range (ATR)
- ATYR 0.22
- NKSH 1.05
- MACD
- ATYR -0.03
- NKSH -0.38
- Stochastic Oscillator
- ATYR 30.00
- NKSH 0.00
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.